Saudi Pharmaceutical Journal最新文献

{"title":"A critical review of workplace drug testing methods for old and new psychoactive substances: Gaps, advances, and perspectives","authors":"Ahmed Ibrahim Al-Asmari","doi":"10.1016/j.jsps.2024.102065","DOIUrl":"https://doi.org/10.1016/j.jsps.2024.102065","url":null,"abstract":"<div><p>Workplace drug testing (WDT) is essential to prevent drug abuse disorders among the workforce because it can impair work performance and safety. However, WDT is limited by many challenges, such as urine adulteration, specimen selection, and new psychoactive substances (NPS). This review examined the issues related to WDT. Various scientific databases were searched for articles on WDT for drug detection published between 1986 (when WDT started) and January 2024. The review discussed the history, importance, and challenges of WDT, such as time of specimen collection/testing, specimen adulteration, interference in drug testing, and detection of NPS. It evaluated the best methods to detect NPS in forensic laboratories. Moreover, it compared different techniques that can enhance WDT, such as immunoassays, targeted mass spectrometry, and nontargeted mass spectrometry. These techniques can be used to screen for known and unknown drugs and metabolites in biological samples. This review assessed the strengths and weaknesses of such techniques, such as their validation, identification, library search, and reference standards. Furthermore, this review contrasted the benefits and drawbacks of different specimens for WDT and discussed studies that have applied these techniques for WDT. WDT remains the best approach for preventing drug abuse in the workplace, despite the challenges posed by NPS and limitations of the screening methods. Nontargeted techniques using high-resolution liquid chromatography-mass spectrometry (MS)/gas chromatography–tandem MS can improve the detection and identification of drugs during WDT and provide useful information regarding the prevalence, trends, and toxicity of both traditional and NPS drugs. Finally, this review suggested that WDT can be improved by using a combination of techniques, multiple specimens, and online library searches in case of new NPS as well as by updating the methods and databases to include new NPS and metabolites as they emerge. To the best of the author's knowledge, this is the first review to address NPS as an issue in WDT and its application and propose the best methods to detect these substances in the workplace environment.</p></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 5","pages":"Article 102065"},"PeriodicalIF":4.1,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1319016424001154/pdfft?md5=b3ec1bb8b51be956d62a0e58b47861e2&pid=1-s2.0-S1319016424001154-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140551755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sorafenib and Piperine co-loaded PLGA nanoparticles: Development, characterization, and anti-cancer activity against hepatocellular carcinoma cell line","authors":"Sulaiman S. Alhudaithi ,&nbsp;Mohd Abul Kalam ,&nbsp;Lama Binobaid ,&nbsp;Raisuddin Ali ,&nbsp;Mohammed M. Almutairi ,&nbsp;Wajhul Qamar ,&nbsp;Hessa Bin Hithlayn ,&nbsp;Atheer Almutairi ,&nbsp;Abdullah K. Alshememry","doi":"10.1016/j.jsps.2024.102064","DOIUrl":"https://doi.org/10.1016/j.jsps.2024.102064","url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) exhibits high mortality rates in the advanced stage (&gt;90 %). Sorafenib (SORA) is a targeted therapy approved for the treatment of advanced HCC; however, the reported response rate to such a therapeutic is suboptimal (&lt;3%). Piperine (PIP) is an alkaloid demonstrated to exert a direct tumoricidal activity in HCC and improve the pharmacokinetic profiles of anticancer drugs including SORA. In this study, we developed a strategy to improve efficacy outcomes in HCC using PIP as an add-on treatment to support the first-line therapy SORA using biodegradable Poly (D, L-Lactide-co-glycolide, PLGA) nanoparticles (NPs). SORA and PIP (both exhibit low aqueous solubility) were co-loaded into PLGA NPs (PNPs) and stabilized with various concentrations of polyvinyl alcohol (PVA). The SORA and PIP-loaded PNPs (SP-PNPs) were characterized using Fourier Transform Infrared (FTIR) Spectroscopy, X-ray Powder Diffraction (XRD), Dynamic Light Scattering (DLS), and Scanning Electron Microscopy (SEM), Release of these drugs from SP-PNPs was investigated <em>in vitro</em> at both physiological and acidic pH, and kinetic models were employed to assess the mechanism of drug release. The <em>in vitro</em> efficacy of SP-PNPs against HCC cells (HepG2) was also evaluated. FTIR and XRD analyses revealed that the drugs encapsulated in PNPs were in an amorphous state, with no observed chemical interactions among the drugs or excipients. Assessment of drug release <em>in vitro</em> at pH 5 and 7.4 showed that SORA and PIP loaded in PNPs with 0.5 % PVA were released in a sustained manner, unlike pure drugs, which exhibited relatively fast release. SP-PNPs with 0.5 % PVA were spherical, had an average size of 224 nm, and had a high encapsulation efficiency (SORA ∼ 82 %, PIP ∼ 79 %), as well as superior cytotoxicity compared to SORA monotherapy <em>in vitro</em>. These results suggest that combining PIP with SORA using PNPs may be an effective strategy for the treatment of HCC and may set the stage for a comprehensive <em>in vivo</em> study to evaluate the efficacy and safety of this novel formulation using a murine HCC model.</p></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 5","pages":"Article 102064"},"PeriodicalIF":4.1,"publicationDate":"2024-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1319016424001142/pdfft?md5=fd08dcae2bd9f3976c80e36251bd5ed0&pid=1-s2.0-S1319016424001142-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140539262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “A narrative review of approved and emerging anti-obesity medications” [Saudi Pharm. J. 31(10) (2023) 101757]","authors":"Semira Abdi Beshir ,&nbsp;Asim Ahmed Elnour ,&nbsp;Aadith Soorya ,&nbsp;Affana Parveen Mohamed ,&nbsp;Sheron Sir Loon Goh ,&nbsp;Nadia Hussain ,&nbsp;Amal H.I. Al Haddad ,&nbsp;Faizah Hussain ,&nbsp;Israa Yousif EL Khidir ,&nbsp;Zainab Abdelnassir","doi":"10.1016/j.jsps.2024.102047","DOIUrl":"https://doi.org/10.1016/j.jsps.2024.102047","url":null,"abstract":"","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 5","pages":"Article 102047"},"PeriodicalIF":4.1,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1319016424000975/pdfft?md5=41d7d90fb0d4bae13efcb5af1d2e010b&pid=1-s2.0-S1319016424000975-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140347084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling potent Schiff base derivatives with selective xanthine oxidase inhibition: In silico and in vitro approach","authors":"Fatna Bellahcene ,&nbsp;Khedidja Benarous ,&nbsp;Arif Mermer ,&nbsp;Houssem Boulebd ,&nbsp;Talia Serseg ,&nbsp;Abderahmane Linani ,&nbsp;Alaeddine Kaouka ,&nbsp;Mohamed Yousfi ,&nbsp;Asad Syed ,&nbsp;Abdallah M. Elgorban ,&nbsp;Yasuhiro Ozeki ,&nbsp;Sarkar M.A. Kawsar","doi":"10.1016/j.jsps.2024.102062","DOIUrl":"https://doi.org/10.1016/j.jsps.2024.102062","url":null,"abstract":"<div><p>This research describes the synthesis by an environmentally-friendly method, microwave irradiation, development and analysis of three novel and one previously identified Schiff base derivative as a potential inhibitor of bovine xanthine oxidase (BXO), a key enzyme implicated in the progression of gout. Meticulous experimentation revealed that these compounds (<strong>10</strong>, <strong>9</strong>, <strong>4</strong>, and <strong>7</strong>) have noteworthy inhibitory effects on BXO, with IC50 values ranging from 149.56 µM to 263.60 µM, indicating their good efficacy compared to that of the standard control. The validation of these results was further enhanced through comprehensive in silico studies, which revealed the pivotal interactions between the inhibitors and the catalytic sites of BXO, with a particular emphasis on the imine group (-C = N-) functionalities. Intriguingly, the compounds exhibiting the highest inhibition rates also showcase advantageous ADMET profiles, alongside encouraging initial assessments via PASS, hinting at their broad-spectrum potential. The implications of these findings are profound, suggesting that these Schiff base derivatives not only offer a new vantage point for the inhibition of BXO but also hold considerable promise as innovative therapeutic agents in the management and treatment of gout, marking a significant leap forward in the quest for more effective gout interventions.</p></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 5","pages":"Article 102062"},"PeriodicalIF":4.1,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1319016424001129/pdfft?md5=7207201b9c4a4e327df6fc7c1195b88c&pid=1-s2.0-S1319016424001129-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140533390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ketamine-based Sedation Use in Mechanically Ventilated Critically Ill Patients with COVID-19: A Multicenter Cohort Study","authors":"Ohoud Aljuhani ,&nbsp;Khalid Al Sulaiman ,&nbsp;Ghazwa B. Korayem ,&nbsp;Ali F. Altebainawi ,&nbsp;Abdulrahman Alshaya ,&nbsp;Majed Nahari ,&nbsp;Khuzama Alsamnan ,&nbsp;Munirah A. Alkathiri ,&nbsp;Bodoor S. Al-Dosari ,&nbsp;Abeer A. Alenazi ,&nbsp;Samiah Alsohimi ,&nbsp;Lina I. Alnajjar ,&nbsp;Mashael Alfaifi ,&nbsp;Nora AlQussair ,&nbsp;Reem M. Alanazi ,&nbsp;Munirah F. Alhmoud ,&nbsp;Nadin L. Alanazi ,&nbsp;Hadeel Alkofide ,&nbsp;Aljawharah M. Alenezi ,&nbsp;Ramesh Vishwakarma","doi":"10.1016/j.jsps.2024.102061","DOIUrl":"https://doi.org/10.1016/j.jsps.2024.102061","url":null,"abstract":"<div><h3>Backgrounds</h3><p>Ketamine possesses analgesia, anti-inflammation, anticonvulsant, and neuroprotection properties. However, the evidence that supports its use in mechanically ventilated critically ill patients with COVID-19 is insufficient. The study's goal was to assess ketamine's effectiveness and safety in critically ill, mechanically ventilated (MV) patients with COVID-19.</p></div><div><h3>Methods</h3><p>Adult critically ill patients with COVID-19 were included in a multicenter retrospective-prospective cohort study. Patients admitted between March 1, 2020, and July 31, 2021, to five ICUs in Saudi Arabia were included. Eligible patients who required MV within 24 hours of ICU admission were divided into two sub-cohort groups based on their use of ketamine (Control vs. Ketamine). The primary outcome was the length of stay (LOS) in the hospital. P/F ratio differences, lactic acid normalization, MV duration, and mortality were considered secondary outcomes. Propensity score (PS) matching was used (1:2 ratio) based on the selected criteria.</p></div><div><h3>Results</h3><p>In total, 1,130 patients met the eligibility criteria. Among these, 1036 patients (91.7 %) were in the control group, whereas 94 patients (8.3 %) received ketamine. The total number of patients after PS matching, was 264 patients, including 88 patients (33.3 %) who received ketamine. The ketamine group's LOS was significantly lower (beta coefficient (95 % CI): −0.26 (−0.45, −0.07), P = 0.008). Furthermore, the PaO2/FiO2 ratio significantly improved 24 hours after the start of ketamine treatment compared to the pre-treatment period (6 hours) (124.9 (92.1, 184.5) vs. 106 (73.1, 129.3; P = 0.002). Additionally, the ketamine group had a substantially shorter mean time for lactic acid normalization (beta coefficient (95 % CI): −1.55 (−2.42, −0.69), P 0.01). However, there were no significant differences in the duration of MV or mortality.</p></div><div><h3>Conclusions</h3><p>Ketamine-based sedation was associated with lower hospital LOS and faster lactic acid normalization but no mortality benefits in critically ill patients with COVID-19. Thus, larger prospective studies are recommended to assess the safety and effectiveness of ketamine as a sedative in critically ill adult patients.</p></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 5","pages":"Article 102061"},"PeriodicalIF":4.1,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1319016424001117/pdfft?md5=0c96de1f613524eb88838a45ba4548e3&pid=1-s2.0-S1319016424001117-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140351404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pioglitazone enhances cisplatin’s impact on triple-negative breast cancer: Role of PPARγ in cell apoptosis","authors":"Qamraa Hamad Alqahtani ,&nbsp;Layla Abdullah Alkharashi ,&nbsp;Hanaa Alajami ,&nbsp;Ishraq Alkharashi ,&nbsp;Layan Alkharashi ,&nbsp;Shoug Nasser Alhinti","doi":"10.1016/j.jsps.2024.102059","DOIUrl":"https://doi.org/10.1016/j.jsps.2024.102059","url":null,"abstract":"<div><p>Peroxisome proliferator-activated receptor-gamma (PPARγ) has been recently shown to play a role in many cancers. The breast tissue of triple-negative breast cancer (TNBC) patients were found to have a significantly lower expression of PPARγ than the other subtypes. Furthermore, PPARγ activation was found to exert anti-tumor effects by inhibiting cell proliferation, differentiation, cell growth, cell cycle, and inducing apoptosis. To start with, we performed a bioinformatic analysis of data from OncoDB, which showed a lower expression pattern of PPAR_γ in different cancer types. In addition, high expression of PPAR_γ was associated with better breast cancer patient survival. Therefore, we tested the impact of pioglitazone, a PPARγ ligand, on the cytotoxic activity of cisplatin in the TNBC cell line. MDA-MB-231 cells were treated with either cisplatin (40 μM) with or without pioglitazone (30 or 60 μM) for 72 h. The MTT results showed a significant dose-dependent decrease in cell viability as a result of using cisplatin and pioglitazone combination compared with cisplatin alone. In addition, the protein expression of Bcl-2, a known antiapoptotic marker, decreased in the cells treated with cisplatin and pioglitazone combination at doses of 40 and 30 μM, respectively. On the other hand, cleaved- poly-ADP ribose polymerase (PARP) and -caspase-9, which are known as pro-apoptotic markers, were upregulated in the combination group compared with the solo treatments. Taken together, the addition of pioglitazone to cisplatin further reduced the viability of MDA-MB-231 cells and enhanced apoptosis compared with chemotherapy alone.</p></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 5","pages":"Article 102059"},"PeriodicalIF":4.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1319016424001099/pdfft?md5=a3e6a9e944c90b96a7c01738da274c5e&pid=1-s2.0-S1319016424001099-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140345204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population pharmacokinetics of gentamicin in acute lymphoblastic leukemia pediatric patients compared to non-oncology patients","authors":"Hisham S. Abou-Auda ,&nbsp;Fatimah Alotaibi ,&nbsp;Sary Alsanea ,&nbsp;Abdulrahman Alwhaibi ,&nbsp;Mohammed M. Almutairi ,&nbsp;Ziyad Alrabiah ,&nbsp;Abdullah Alsultan ,&nbsp;Majed Al Jeraisy","doi":"10.1016/j.jsps.2024.102060","DOIUrl":"https://doi.org/10.1016/j.jsps.2024.102060","url":null,"abstract":"<div><p>Understanding the pharmacokinetics of gentamicin is essential in special populations, such as pediatric patients with acute lymphoblastic leukemia (ALL), in light of previous studies indicating that ALL patients have a lower volume of distribution than non-ALL patients. Furthermore, validation of such results is needed to ensure their clinical application. Accordingly, this single-center, retrospective, cross-sectional study compares the pharmacokinetic parameters of volume of distribution and clearance (Cl) of gentamicin between ALL and non-ALL patients. Inclusion criteria were pediatric patients aged between 1 and 14 years with or without ALL and receiving intravenous gentamicin for treatment courses &gt; 72 h. Patients’ characteristics, such as age, sex, height, serum albumin, diagnosis, serum creatinine (Scr) concentration, dosing, and pharmacokinetic information, including peak and trough concentrations, were retrieved. The study scrutinized a total of 115 pediatric patients, comprising toddlers (15.7 %), children (76.5 %), and adolescents (7.8 %). All patients received gentamicin every 8 h, with an average dose of 2.50 (0.64) mg/kg. Patients were divided into two groups based on disease state, with 45.2 % (n = 52) in the non-ALL group and 54.8 % (n = 63) in the ALL group. Both groups had similar characteristics in terms of gender, weight, body surface area, and dose. The only significant covariates identified were weight and creatinine clearance (Cl_cr) for volume of distribution (V_d). A significant difference was found in Scr, Cl_cr, and blood urea nitrogen (BUN); however, no significant difference between ALL and non-ALL patients emerged in the volume of distribution or Cl. In conclusion, the study findings indicate that dosing requirements were similar between the two groups. Further prospective studies with larger sample sizes are warranted.</p></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 5","pages":"Article 102060"},"PeriodicalIF":4.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1319016424001105/pdfft?md5=8cd2620e881b8cae9a540474a16924a8&pid=1-s2.0-S1319016424001105-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140346934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fabrication and evaluation of ribavirin-loaded electrospun nanofibers as an antimicrobial wound dressing","authors":"Khulud A. Alsulami ,&nbsp;Abrar A. Bakr ,&nbsp;Abdullah A. Alshehri ,&nbsp;Alhassan H. Aodah ,&nbsp;Fahad A. Almughem ,&nbsp;Ali A. Alamer ,&nbsp;Lujain A. Alharbi ,&nbsp;Deema S. Alsuwayeh ,&nbsp;Abdulrahman A. Halwani ,&nbsp;Abdullah A. Alamoudi ,&nbsp;Haya A. Alfassam ,&nbsp;Essam A. Tawfik","doi":"10.1016/j.jsps.2024.102058","DOIUrl":"https://doi.org/10.1016/j.jsps.2024.102058","url":null,"abstract":"<div><h3>Background</h3><p>Skin is regarded as an essential first line of defense against harmful pathogens and it hosts an ecosystem of microorganisms that create a widely diverse skin microbiome. In chronic wounds, alterations in the host-microbe interactions occur forming polymicrobial biofilms that hinder the process of wound healing. Ribavirin, an antiviral drug, possesses antimicrobial activity, especially against <em>Pseudomonas aeruginosa</em> and <em>Candida albicans</em>, which are known as the main opportunistic pathogens in chronic wounds.</p></div><div><h3>Rationale</h3><p>In this study, electrospun nanofiber systems loaded with ribavirin were developed as a potential wound dressing for topical application in chronic wounds. Ribavirin was chosen in this study owing to the emerging cases of antimicrobial (antibiotics and antifungal) resistance and the low attempts to discover new antimicrobial agents, which encouraged the repurposing use of current medication as an alternative solution in case of resistance to the available agents. Additionally, the unique mechanism of action of ribavirin, i.e., perturbing the bacterial virulence system without killing or stopping their growth and rendering the pathogens disarmed, might be a promising choice to prevent drug resistance. Cyclodextrin (CD) was utilized to formulate ribavirin as an electrospun nanofibers delivery system to enhance the absorption and accelerate the release of ribavirin for topical use.</p></div><div><h3>Results</h3><p>The results demonstrated a successful ribavirin nanofibers fabrication that lacked beads and pores on the nanofibrous surfaces. Ribavirin underwent a physical transformation from crystalline to amorphous form, as confirmed by X-ray diffraction analysis. This change occurred due to the molecular dispersion after the electrospinning process. Additionally, the CD enhanced the encapsulation efficiency of ribavirin in the nanofibers as observed from the drug-loading results. Polyvinylpyrrolidone (PVP) and CD increased ribavirin released into the solution and the disintegration of fibrous mats which shrank and eventually dissolved into a gel-like substance as the ribavirin-loaded fibers began to break down from their border toward the midpoint. Cytotoxicity of ribavirin and CD was evaluated against human dermal fibroblasts (HFF-1) and the results showed a relatively safe profile of ribavirin upon 24-hour cell exposure, while CD was safe within 24- and 48-hour.</p></div><div><h3>Conclusion</h3><p>This study provides valuable insights into the potential application of our nanofibrous system for treating chronic wounds; however, further antimicrobial and <em>in-vivo</em> studies are required to confirm its safety and effectiveness.</p></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 5","pages":"Article 102058"},"PeriodicalIF":4.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1319016424001087/pdfft?md5=641caec03c9355e0f5921bb8915ed05a&pid=1-s2.0-S1319016424001087-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140345232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological p38 MAPK inhibitor SB203580 enhances AML stem cell line KG1a chemosensitivity to daunorubicin by promoting late apoptosis, cell growth arrest in S-phase, and miR-328-3p upregulation","authors":"Sara Bahattab ,&nbsp;Ali Assiri ,&nbsp;Yazeid Alhaidan ,&nbsp;Thadeo Trivilegio ,&nbsp;Rehab AlRoshody ,&nbsp;Sarah Huwaizi ,&nbsp;Bader Almuzzaini ,&nbsp;Abir Alamro ,&nbsp;Manal Abudawood ,&nbsp;Zeyad Alehaideb ,&nbsp;Sabine Matou-Nasri","doi":"10.1016/j.jsps.2024.102055","DOIUrl":"10.1016/j.jsps.2024.102055","url":null,"abstract":"<div><p>Acute myeloid leukaemia (AML) is characterized by uncontrolled proliferation of myeloid progenitor cells and impaired maturation, leading to immature cell accumulation in the bone marrow and bloodstream, resulting in hematopoietic dysfunction. Chemoresistance, hyperactivity of survival pathways, and miRNA alteration are major factors contributing to treatment failure and poor outcomes in AML patients. This study aimed to investigate the impact of the pharmacological p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 on the chemoresistance potential of AML stem cell line KG1a to the therapeutic drug daunorubicin (DNR). KG1a and chemosensitive leukemic HL60 cells were treated with increasing concentrations of DNR. Cell Titer-Glo®, flow cytometry, phosphokinase and protein arrays, Western blot technology, and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were employed for assessment of cell viability, half-maximal inhibitory concentration (IC₅₀) determination, apoptotic status detection, cell cycle analysis, apoptosis-related protein and gene expression monitoring. Confocal microscopy was used to visualize caspase and mitochondrial permeability transition pore (mPTP) activities. Exposed at various incubation times, higher DNR IC₅₀ values were determined for KG1a cells than for HL60 cells, confirming KG1a cell chemoresistance potential. Exposed to DNR, late apoptosis induction in KG1a cells was enhanced after SB203580 pretreatment, defined as the combination treatment. This enhancement was confirmed by increased cleavage of poly(ADP-ribose) polymerase, caspase-9, caspase-3, and augmented caspase-3/-7 and mPTP activities in KG1a cells upon combination treatment, compared to DNR. Using phosphokinase and apoptosis protein arrays, the combination treatment decreased survival Akt phosphorylation and anti-apoptotic Bcl-2 expression levels in KG1a cells while increasing the expression levels of the tumor suppressor p53 and cyclin-dependent kinase inhibitor p21, compared to DNR. Cell cycle analysis revealed KG1a cell growth arrest in G2/M-phase caused by DNR, while combined treatment led to cell growth arrest in S-phase, mainly associated with cyclin B1 expression levels. Remarkably, the enhanced KG1a cell sensitivity to DNR after SB203580 pretreatment was associated with an increased upregulation of miR-328-3p and slight downregulation of miR-26b-5p, compared to DNR effect. Altogether, these findings could contribute to the development of a new therapeutic strategy by targeting the p38 MAPK pathway to improve treatment outcomes in patients with refractory or relapsed AML.</p></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 6","pages":"Article 102055"},"PeriodicalIF":4.1,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1319016424001051/pdfft?md5=6eeef7e1d7b61b8a83aef989981927fb&pid=1-s2.0-S1319016424001051-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140400195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arabic translation and cultural adaptation of Hill-Bone compliance to high blood pressure therapy scale","authors":"Ibrahim Sales ,&nbsp;Yazed AlRuthia","doi":"10.1016/j.jsps.2024.102053","DOIUrl":"https://doi.org/10.1016/j.jsps.2024.102053","url":null,"abstract":"<div><h3>Background</h3><p>Adherence to prescription medications is vital to the success of any treatment plan, especially for chronic health conditions, such as hypertension (HTN). Although there are different scales used in assessing adherence to prescription medications, most if not all, of those scales are not available in Arabic. The absence of essential assessment tools makes the appraisal of adherence to prescription medications very difficult for native Arabic speakers. Therefore, this study aimed to translate and validate the Hill-Bone Compliance to High Blood Pressure Therapy (CHBPT) scale, which is commonly used to assess adherence to antihypertensive medications, among a sample of Arabic-speaking patients with HTN.</p></div><div><h3>Methods</h3><p>This was a single-center cross-sectional study that took place at a university-affiliated hospital. It interviewed adult (≥18 years) patients with HTN who were visiting the primary care clinics between January and November 2020. Non-Arabic speakers, those under 18 years of age, individuals without a diagnosis of HTN, and patients without any previously filled prescription medications for HTN within the past three months were excluded. The forward–backward translation method was used after receiving permission from the originators of the questionnaire to translate their scale to Arabic. Test-retest and Cronbach alpha methods were used to assess the reliability. Principal component analysis with varimax rotation was used to examine the construct validity.</p></div><div><h3>Results</h3><p>One hundred and forty-one patients consented and participated in the study. Most of the patients were ≥ 50 years old (75 %), male (72 %), and had another chronic health condition besides HTN (99 %). The translated scale had good internal consistency (Cronbach alpha = 0.83) and reliability (intraclass correlation coefficient of 0.9). The Kaiser-Meyer-Oklin was 0.82 indicating adequate sampling to conduct factor analysis; hence, three factors (e.g., subscales) were extracted similar to the original scale. The mean scores for appointment keeping, medication taking, and reducing sodium intake subscales, as well as for the overall scale were 5.62 ± 1.39, 33.94 ± 3.87, 9.73 ± 2.1, and 49.29 ± 5.21, respectively.</p></div><div><h3>Conclusion</h3><p>The translated version of the Hill-Bone CHBPT scale has both good reliability and validity and will hopefully help healthcare providers assess and monitor HTN patients’ adherence to their antihypertensive medication regimens. Multicenter studies should be conducted to verify the validity and reliability of the translated questionnaire among different Arabic-speaking patient populations with HTN.</p></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 5","pages":"Article 102053"},"PeriodicalIF":4.1,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1319016424001038/pdfft?md5=28672814422838b51877b0d590f4533d&pid=1-s2.0-S1319016424001038-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140342278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}